Home > Search Clinical Trials > Gastrointestinal (Stomach, Bowel, Etc.)
Clinical Trials: Gastrointestinal (Stomach, Bowel, Etc.)
IRB No. 16-170J-1 (Dr. Thomas Devers, PI): Microbiome analysis in C. Difficile Infection and Fecal Microbiota Transplant
Clostridium difficile is a bacteria which causes life-threatening inflammation of the colon, infection and diarrhea. C. difficile infection (CDI) is difficult to treat and is associated with a high rate of antibiotic failure. Recurrence of CDI is common and occurs in 30 - 65% of patients. The recent development of Fecal Microbiota Transplant (FMT) stool transplant therapy, that involves the infusion of stool from a healthy donor into the infected colon, has demonstrated effectiveness in curing CDI. This research study will involve close collaboration between gastroenterologists at UConn Health and Microbial Genomics at the Jackson Laboratory for Genomic Medicine (JAX-GM). The specific aims of this project include identification and analysis of specific gut bacteria using genomic microbial analysis techniques in patients with C. Difficile infection pre- and post- stool transplant and of the healthy stool transplant donor. Through these analyses, we will gain a better understanding of the changes to the intestinal bacterial communities in Clostridium Difficile infection before and after FMT. This research may eventually lead to novel therapies by identification and isolation of intestinal bacteria associated with both infection and cure of CDI.